Literature DB >> 12368145

[Antiganglioside autoantibody profiles in Guillain-Barré syndrome].

C Caudie1, C Vial, J Bancel, P Petiot, J C Antoine, P M Gonnaud.   

Abstract

We established anti-ganglioside antibody profiles in GBS and studied the frequency, fine specificity and clinical correlate. IgG and IgM antibodies to 8 gangliosides were tested by immunodot-blot in 249 consecutive patients with Guillain-Barré syndrome with large variability in clinical expression, referred to our laboratory over a 8-year period. IgG and IgM anti-GM1 antibodies were measured by Elisa. Thin-layer chromatography overlayed by serum was used to control positivity. 89/249 GBS (36%) had characteristic anti-ganglioside antibody profile. Isotypes were, IgG (62%), IgG + IgM (26%) and IgM (12%). Antecedent infections were found in 62% of GBS included more frequently Campylobacter jejuni and cytomegalovirus. Various autoantibody profiles were described with an immunodominant ganglioside. We detected 6 characteristic anti-ganglioside profiles with fine specificity and immunodominant ganglioside corresponding to 6 immuno-clinical variants of GBS: 1) anti-GM1 and GD1b IgG and IgG > IgM in the acute motor axonal neuropathy after Campylobacter jejuni infection in 41 GBS; 2) anti-GD1a IgG in 6 severe motor axonal GBS after Campylobacter jejuni infection; 3) selectively anti-GQ1b IgG in 17 typical Miller Fisher syndrome with areflexia, ataxia and ophthalmoplegia; 4) anti- GT1b ganglioside and polysialogangliosides IgG (n = 9) in two separate cranial nerve variants, ophthalmoplegic SGB and lower cranial nerve variants depending upon the presenting deficit; 5) anti-GD1b IgG in 5 pure ataxic sensory GBS (4%); 6) anti-GM2 IgM in 11 severe GBS with antecedent CMV infection (8%). 34 GBS (14%) had low levels of anti-GM1 and GD1b IgM antibodies which are not disease specific and may simply represent part of the naturally occurring autoantibody population or a secondary response to disease. 126 GBS (50%) had no antibodies, predominantly in classical form. Associations between isotype, fine specificity and clinical presentation permit the definition of homogeneous immuno-clinical variants. Various autoantibody profiles with diagnostic and prognostic value are easy to perform by immunodot blot in acute peripheral neuropathies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368145

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  5 in total

1.  Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients.

Authors:  Christiane Caudie; Arnaud Quittard Pinon; Didier Taravel; Valérie Sivadon-Tardy; David Orlikowski; Flore Rozenberg; Tarek Sharshar; Jean Claude Raphaël; Jean Louis Gaillard
Journal:  J Neurol       Date:  2011-04-24       Impact factor: 4.849

2.  Anti-GM2 ganglioside antibodies are a biomarker for acute canine polyradiculoneuritis.

Authors:  Angie Rupp; Francesc Galban-Horcajo; Ezio Bianchi; Maurizio Dondi; Jacques Penderis; Joanna Cappell; Karl Burgess; Kaspar Matiasek; Rhona McGonigal; Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2013-03       Impact factor: 3.494

3.  Association of anti-gangliosides antibodies and anti-CMV antibodies in Guillain-Barré syndrome.

Authors:  Lijuan Wang; Chunqing Shao; Chunjiao Yang; Xixiong Kang; Guojun Zhang
Journal:  Brain Behav       Date:  2017-04-07       Impact factor: 2.708

4.  Correlations between cytomegalovirus, Epstein-Barr virus, anti-ganglioside antibodies, electrodiagnostic findings and functional status in Guillain-Barré syndrome.

Authors:  Aliakbar Taheraghdam; Peyman Pourkhanjar; Mahnaz Talebi; Mohammadreza Bonyadi; Ali Pashapour; Ehsan Sharifipour; Reza Rikhtegar
Journal:  Iran J Neurol       Date:  2014

5.  Most of anti-glycolipid IgG-antibodies associated to neurological disorders occur without their IgM counterpart.

Authors:  Ricardo Dante Lardone; Fernando José Irazoqui; Gustavo Alejandro Nores
Journal:  J Biomed Sci       Date:  2019-09-06       Impact factor: 8.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.